

Note: This document is a direct translation of the document released in Japanese. If there are any discrepancies between this document and the original Japanese version, the original Japanese version prevails.

Tokyo, June 4, 2025

## FOR IMMEDIATE RELEASE

### **(Amendment) Partial amendments to the “Announcement of Expression of Opinion in Support of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Recommendation to Tender Shares in the Tender Offer”**

With regard to the “Announcement of Expression of Opinion in Support of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Recommendation to Tender Shares in the Tender Offer” released by TORII PHARMACEUTICAL CO., LTD. (the “Company”) on May 7, 2025 (the “Company’s Press Release dated May 7, 2025”), the Company hereby announces as follows because the situation which requires partial amendments to the details thereof (the “Amendments”) occurred.

As stated in the “(Amendment) Notice of Amendment to “Notice of Commencement of Tender Offer for Shares of TORII PHARMACEUTICAL CO., LTD. (Securities Code: 4551)” and Public Notice of Commencement of Tender Offer Due to Submission of Amendment to Tender Offer Statement” released by Shionogi & Co., Ltd. (the “Tender Offeror”) today, the Company made the Amendments due to the Tender Offeror’s submission to the Kanto Local Finance Bureau of the amendment to the tender offer statement regarding the Tender Offeror’s tender offer for shares of the Company’s common stock in accordance with the Financial Instruments and Exchange Act (Act No. 25 of 1948, as amended) (the “Act”).

In addition, the Company was informed that the Amendments do not intend to amend the terms and conditions of purchase, etc. defined in Article 27-3, paragraph (2), item (i) of the Act. Please note that the amended parts have been underlined.

#### 11. Other Information (Before amendment)

- (1) Release of “Notice Regarding Revision of the Interim and Year-end Dividend Forecasts (Nil Dividend) for the Fiscal Year Ending December 2025”

At its Board of Directors meeting held today, the Company adopted a resolution to pay no interim dividend and no year-end dividend for the fiscal year ending December 2025. For details, please see “Notice Regarding Revision of the Interim and Year-end Forecasts (Nil Dividend) for the Fiscal Year Ending December 2025” released today.

#### (After amendment)

- (1) Release of “Notice Regarding Revision of the Interim and Year-end Dividend Forecasts (Nil Dividend) for the Fiscal Year Ending December 2025”

At its Board of Directors meeting held on May 7, 2025, the Company adopted a resolution to pay no interim dividend and no year-end dividend for the fiscal year ending December 2025. For details, please see “Notice Regarding Revision of the Interim and Year-end Forecasts (Nil Dividend) for the Fiscal Year Ending December 2025” released on May 7, 2025.

- (2) Release of “Our relationship with Patent Infringement Lawsuit regarding Drug Use Patent Pertaining to Oral Antipruritus Medication “REMITCH®” announced by Toray Industries, Inc. on May 27, 2025”

The Company released today “Our relationship with Patent Infringement Lawsuit regarding Drug Use Patent

Pertaining to Oral Antipruritus Medication “REMITCH®” announced by Toray Industries, Inc. on May 27, 2025” (the “Case”). For details, please see the details of the said announcement. Please note that there is no change in the Company’s opinion on the Tender Offer because (1) the date the Company can record its revenues and the amount of revenues to be recorded remain to be unclear at this point of time as the ruling on the said patent infringement lawsuit has not been finalized, (2) the Company carried out the negotiation with the Tender Offeror regarding the Tender Offer after the Company was subject to the Tender Offeror’s various due diligences and informed the Tender Offeror of the status at the time of the said patent infringement lawsuit and summary of the agreement between the Company and Toray Industries, Inc. and (3) the evaluation of the Tender Offer Price stated in “(c) The Company’s Decision-Making Process Leading to Its Decision to Support the Tender Offer and Reasons Therefor” of “(2) Grounds and Reasons for the Company’s Opinion on the Tender Offer” of “3. Details of, and Grounds and Reasons for, the Company’s Opinion on the Tender Offer” will not be changed due to the Case.

End